INSULET CORP reported revenue of $0.80B for the period ended 2026-06-30, +23.5% year on year. Net income was $0.10B, a 11.8% net margin on a 70.2% gross margin. The largest revenue line is U.S.Omnipod at 68% of the total. Free cash flow for the period was $0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $0.80B | +23.5% |
| Gross profit | $0.56B | — |
| Operating income | $0.13B | — |
| Net income | $0.10B | +322.2% |
| Gross margin | 70.2% | Net margin 11.8% |
| Revenue Q/Q | +5.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| U.S.Omnipod | $0.54B | 67.9% |
| International Omnipod | $0.25B | 31.4% |
| Drug Delivery | $0.01B | 0.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.24B | 29.8% |
| R&D | $0.09B | 11.0% |
| SG&A | $0.34B | 43.0% |
| Tax & other | $0.03B | 4.3% |
| Item | Amount |
|---|---|
| Total assets | $3.17B |
| Total liabilities | $1.74B |
| Shareholders' equity | $1.42B |
| Equity / assets | 44.9% |
| Operating cash flow | $0.09B |
| Capital expenditure | $0.04B |
| Free cash flow | $0.05B |
| Cash conversion (OCF / net income) | 93% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
INTC ・ IBKR ・ ICE ・ IFF ・ IP ・ INTU ・ ISRG ・ IVZ ・ INVH ・ IQV ・ IRM ・ JBHT
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies